NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.74 (-0.93%) GOLD FUTURES
2,425.20 -13.30 (-0.55%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
54,767.77 +253.52 (+0.47%)
Century Therapeutics, Inc. (IPSC)
After hours:
| Previous close | 3.0000 |
| Open | 3.0000 |
| Bid | 2.9100 x 100 |
| Ask | 3.0400 x 100 |
| Day's range | 2.9000 - 3.1600 |
| 52-week range | 1.2800 - 5.5100 |
| Volume | |
| Avg. volume | 123,508 |
| Market cap | 247.035M |
| Beta (5Y monthly) | 1.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.2200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.17 |
- GuruFocus.com
Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ...
Comprehensive Analysis of Financial Performance and Strategic Milestones
GlobeNewswireCentury Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE)Preclinical data demonstrates potential utility of using a synthetic ligand targeting CD300a as a universal strategy for preventing NK mediated rejection in allogeneic cell therapies PHILADELPHIA, May 10, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developi
ZacksCentury Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates
Century Therapeutics (IPSC) delivered earnings and revenue surprises of 10% and 185%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
